Alpha Cognition Inc Price Target Raised to C$2.00/Share From C$1.00 by Raymond James
Alpha Cognition Inc Price Target Raised to C$2.00/Share From C$1.00 by Raymond
Express News | Alpha Cognition Inc Says Applied to List Common Shares on Nasdaq Under Trading Symbol “Acog”
Press Release: Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update VANCOUVER, British Columbia--(BUSINESS WIRE)--May 14, 2024-- Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ("A
Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period
Alpha Cognition Inc. (ACOG.CN), a biopharmaceutical company, overnight Wednesday reported a fourth quarter comprehensive net loss of US$5.8 million, or $(0.05) per basic and diluted share, compared wi
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.
Alpha Cognition Provides Business Update
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of The...
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its filing review and has accepted the company's New Drug Application (NDA) for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer's Disease.
Alpha Cognition Reports Amended Terms of Private Placement, Continuation of the Offering
Alpha Cognition Inc. (ACOG.CSE), which lost near 10% yesterday, overnight Monday said that it has amended the terms of its private placement offering of up to US$6.5 million ($8.8 million) of units at
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
Canadian Securities Exchange Reports May 2023 Performance Figures
Toronto, Ontario--(Newsfile Corp. - June 20, 2023) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for May 2023.May 2023 Operating StatisticsTrading volu
CSE Bulletin: New Listing - Alpha Cognition Inc. (ACOG, ACOG.WT)
Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE. Listing and disclosure documents will be
Alpha Cognition to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023
VANCOUVER, BC / ACCESSWIRE / April 5, 2023 / Alpha Cognition Inc. (TSX-V:ACOG)(OTCQB:ACOGF), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today
Brokers Set Expectations for Alpha Cognition Inc.'s FY2023 Earnings (OTC:ACOGF)
Alpha Cognition Inc. (OTC:ACOGF – Get Rating) – Stock analysts at Zacks Small Cap lifted their FY2023 earnings estimates for Alpha Cognition in a research report issued on Wednesday, March 15th. Za
Alpha Cognition Inc Price Target Cut to C$1.00/Share From C$3.00 by Raymond James
Alpha Cognition Inc Price Target Cut to C$1.00/Share From C$3.00 by Raymond James
Alpha Cognition Inc Price Target Cut to C$3.00/Share From C$4.00 by Raymond James
Alpha Cognition Inc Price Target Cut to C$3.00/Share From C$4.00 by Raymond James
Alpha Cognition Inc Is Maintained at Outperform by Raymond James
Alpha Cognition Inc Is Maintained at Outperform by Raymond James
BRIEF-Alpha Cognition Inc - On Track And Plans To Release Data From Alpha-1062 Pivotal Trial During Q2 Of 2022
May 31 (Reuters) - Alpha Cognition Inc ACOG.V :* ALPHA COGNITION INC - ON TRACK AND PLANS TO RELEASE DATA FROM ALPHA-1062 PIVOTAL TRIAL DURING Q2 OF 2022* ALPHA COGNITION INC - PLANS TO MEET WITH FDA
Alpha Cognition Inc. Is Maintained at Outperform by Raymond James
Alpha Cognition Inc. Is Maintained at Outperform by Raymond James